Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Progressive Metastatic Castrate Resistant Prostate Cancer”

60 trials

Showing 20 of 60 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03042468
What this trial is testing

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

Who this might be right for
Prostate Cancer
Weill Medical College of Cornell University 50
Not applicableStudy completedNCT00578409
What this trial is testing

Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center 758
Testing effectiveness (Phase 2)Ended earlyNCT03531827
What this trial is testing

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Who this might be right for
Metastatic Castration Resistant Prostate CancerProstate Neoplasms
National Cancer Institute (NCI) 4
Large-scale testing (Phase 3)WithdrawnNCT02053311
What this trial is testing

Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents

Who this might be right for
Prostate Cancer
Swiss Cancer Institute
Post-approval studies (Phase 4)Study completedNCT02116582
What this trial is testing

Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Astellas Pharma Europe B.V. 215
Large-scale testing (Phase 3)Ended earlyNCT04876651
What this trial is testing

The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only

Who this might be right for
Metastatic Prostate Cancer
Telix Pharmaceuticals (Innovations) Pty Ltd 16
Testing effectiveness (Phase 2)Ended earlyNCT01828476
What this trial is testing

Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
Rutgers, The State University of New Jersey 13
Not applicableStudy completedNCT06460454
What this trial is testing

PROnostic Interest of 18F-FDG PET/CT in Patients With Metastatic Castration-resistant Prostate Cancer (mCPRC) Progressing

Who this might be right for
Prostate Cancer
Central Hospital, Nancy, France 100
Large-scale testing (Phase 3)Study completedNCT01707966
What this trial is testing

Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy

Who this might be right for
Prostate Cancer
Swiss Cancer Institute 47
Testing effectiveness (Phase 2)Study completedNCT03392428
What this trial is testing

A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Cancer of the ProstateMetastatic Cancer
Australian and New Zealand Urogenital and Prostate Cancer Trials Group 201
Early research (Phase 1)Active Not RecruitingNCT04886986
What this trial is testing

Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Weill Medical College of Cornell University 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT04506567
What this trial is testing

Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC

Who this might be right for
Prostate Cancer
Weill Medical College of Cornell University 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT01688492
What this trial is testing

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center 54
Testing effectiveness (Phase 2)Looking for participantsNCT07206056
What this trial is testing

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

Who this might be right for
Progressive Metastatic Castrate Resistant Prostate Cancer
Novartis Pharmaceuticals 188
Large-scale testing (Phase 3)Ended earlyNCT00676650
What this trial is testing

Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy

Who this might be right for
Prostatic Neoplasms
Pfizer 873
Testing effectiveness (Phase 2)Active Not RecruitingNCT05658003
What this trial is testing

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 63
Testing effectiveness (Phase 2)Ended earlyNCT00479635
What this trial is testing

A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Cortice Biosciences, Inc. 26
Not applicableNot Yet RecruitingNCT07538843
What this trial is testing

An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT Treatment

Who this might be right for
Non-metastatic Castration-resistant Prostate Cancer
Bayer 800
Large-scale testing (Phase 3)Looking for participantsNCT06691984
What this trial is testing

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Amgen 675
Testing effectiveness (Phase 2)UnknownNCT01296243
What this trial is testing

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Genta Incorporated 57
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation